$KRRO: Korro Bio, Inc. - Common Stock

Korro Bio, Inc. is a clinical-stage biopharmaceutical company developing novel treatments for inflammatory and fibrotic diseases. Their lead product candidate, KOR-886, is an oral inhibitor of the complement system and is involved in various inflammatory and fibrotic diseases. KOR-886 is in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and scleroderma, with potential applications in IBD and COPD.

Financial Highlights

• Market Capitalization: $196.99 million as of October 13, 2023
• 52-Week Trading Range: $9.15 to $279.50
• Revenue per Employee: Information not available
• P/E Ratio: Not available
• EPS: -$83.09
• Dividend: No dividend paid
• Ex-Dividend Date: Not available
• Short Interest: 7.32K as of October 13, 2023
• Average Daily Trading Volume: 11.49K

Recent Developments

• Initiated Phase 2 clinical trial for scleroderma treatment in September 2023
• Received Fast Track designation from the FDA for KOR-886 for IPF treatment in August 2023
• Closed a $50 million Series D financing round in July 2023

Investment Outlook

Korro Bio is in the clinical stage with a focus on inflammatory and fibrotic diseases. The company's lead product, KOR-886, has received FDA Fast Track designation and is backed by a strong management team and significant funding. However, as a company in early development stages with no approved commercial products, potential investors should consider the associated risks and rewards.